Go Pro
OTCMKTS:FSNUY

Fresenius SE & Co. Q1 2026 Earnings Report

Fresenius SE & Co. logo
$13.61 -0.05 (-0.40%)
As of 12:54 PM Eastern

Fresenius SE & Co. EPS Results

Actual EPS
$0.24
Consensus EPS
$0.25
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Fresenius SE & Co. Revenue Results

Actual Revenue
$6.75 billion
Expected Revenue
$6.79 billion
Beat/Miss
Missed by -$36.92 million
YoY Revenue Growth
N/A

Fresenius SE & Co. Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, November 4, 2026, based on past reporting schedules.

Conference Call Resources

Fresenius SE & Co. Earnings Headlines

The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
Fresenius SE & Co. KGaASF-MTN v.2024(2029/2029) Bond
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co. brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments. Fresenius Medical Care is the largest provider of renal care products and services, including dialysis machines, disposables and clinic operations. Fresenius Kabi offers a broad range of lifesaving medicines, infusion therapies, clinical nutrition and medical devices for intravenous drug delivery. Fresenius Helios manages a network of acute care hospitals and outpatient facilities across Europe, while Fresenius Vamed specializes in planning, construction and management of healthcare projects and facilities, supporting clients from conception through operation.

Fresenius serves patients and healthcare providers in more than 100 countries, with production sites, research centers and clinical operations spanning Europe, North America, Asia-Pacific and Latin America. The company emphasizes continuous innovation, investing in research and development to enhance patient outcomes and streamline care delivery. Under the leadership of Chief Executive Officer Dr. Stephan Sturm, Fresenius pursues a strategy of geographic expansion and portfolio optimization to address evolving global healthcare needs.

View Fresenius SE & Co. Profile